We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Rad3.2
RAD-140 (Testolone) Research
Mostly mechanism / observationalLimited safety
6 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most RAD-140 (Testolone) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2011–2024 with a typical study size of 22 participants.
Based on 6 studies · 22 total participants
Confidence
Low
By outcome
Muscle & body composition (preclinical)
Mostly mechanism / observational6 studies
Androgen & hormonal axis
Mostly mechanism / observational6 studies
Liver injury
Too few graded studies2 studies
Safety profile
Too few graded studies2 studies
Active research area
4 studies in the last 5 years
201120172024
1Safety, tolerability, MTD, and pharmacokineticsOpen-Labeln=22 · very small study2022
RAD140 is a novel oral AR-targeted agent with an acceptable safety profile and preliminary evidence of target engagement and antitumor activity; the most frequent treatment-emergent adverse events were elevated AST (59.1%) and ALT (45.5%).
LoRusso, Hamilton, Ma, Vidula, Bagley, Troy · Clinical breast cancer (2022)
First-in-human Phase-1 dose-escalation (3+3) — a safety/PK study, not an efficacy RCT
In 23% of samples, the expected SARM was not detected but a different one instead ... Other undeclared pharmaceutical substances (tamoxifen, clomifene, testosterone, epimethandienone, tadalafil) were measured in 30% of samples.
Gaudiano MC, Aureli F, Manna L, Borioni A, Maccelli A, Raimondo M, et al. · Sexual medicine (2024)
Recent (2024) analytical study of 13 SARM products purchased online — reinforces the mislabeling/contamination finding
Qualitative analysis confirmed the stated SARM in only ~70% of samples; 23% contained a different SARM and one contained none; content ranged 30-90% of label claim
30% of products contained undeclared drugs (tamoxifen, clomifene, testosterone, tadalafil) and >60% contained more than one active substance
This report describes the discovery of RAD140, a potent, orally bioavailable, nonsteroidal selective androgen receptor modulator (SARM), characterized in several preclinical models of anabolic androgen action.
RAD140 is a potent AR agonist in breast cancer cells that inhibits the growth of multiple AR/ER+ breast cancer patient-derived xenograft models as a single agent.
Yu, He, Wang, Patel, Miller, Brown · Clinical cancer research (2017)
In-vitro and xenograft (preclinical) study, not a human trial
RAD-140 bound the AR with high affinity and inhibited AR/ER+ breast-cancer growth
Suppressed the ER pathway including the ESR1 gene; effect enhanced with palbociclib
A 22-year-old previously healthy male who took the SARM RAD-140 for 16 weeks developed jaundice and cholestatic liver injury; liver biopsy showed a picture consistent with drug-induced liver injury.
Mohamed, Jahagirdar, Fatima, Ahmed, Jaber, Wang · Cureus (2023)
Human case report: 22-year-old man took RAD-140 for 16 weeks
Presented with jaundice, markedly elevated bilirubin, and cholestatic liver injury
Biopsy consistent with drug-induced liver injury; enzymes normalized 3–12 months after stopping